Expanding the phenotype of HNRNPU-related disorders to include brief, resolved, unexplained events (BRUE) by Scheffler, Jonah et al.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Child Health Research Institute Pediatric 
Research Forum Children’s Hospital & Medical Center 
5-2021 
Expanding the phenotype of HNRNPU-related disorders to include 
brief, resolved, unexplained events (BRUE) 
Jonah Scheffler 
Kristen P. Fishler 
Lois J. Starr 
Follow this and additional works at: https://digitalcommons.unmc.edu/chri_forum 
 Part of the Pediatrics Commons 
Jonah L. Scheffler, Kristen P. Fishler MS, CGC, Lois J. Starr MD, PhD, FAAP, FACMG
1Munroe-Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center, Omaha, NE, United States,
2Children's Hospital and Medical Center, Omaha, NE, United States, 
Expanding the phenotype of HNRNPU-related disorders 
to include brief, resolved, unexplained events (BRUE) 
DISCUSSION / CONCLUSIONS
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Genetic testing including microarray and sequencing studies revealed the variants in Table 1. No genomic dosage anomalies were reported. The 
truncating de novo (c.803+2T>C) variant in HNRNPU was classified as likely pathogenic. This variant may disrupt the canonical splice donor site for exon 2 and 
while this mutation in novel, other canonical splice disrupting variants have been reported to be pathogenic. hnRNPs have a key role in mediating transcription, 
alternative splicing, and translation activity. Alternative splicing can lead to an increase in proteomic diversity. This is necessary for the flexibility of a cancerous 
cell to respond to various environments. There is little research surrounding hnRNP-U and its role in cancer development, but the production of alternative 
transcripts due to dysregulation can lead to aberrant protein isoforms with altered functions [2]. Regarding neurodegenerative diseases, hnRNPs are responsible 
for the regulation of translation at the presynaptic sites as well as the transportation of stabilized mRNAs along the axonal cytoskeleton to these presynaptic 
translation hubs. Deviation from hnRNPs’ normal function can result in multiple neurological diseases, such as ALS/FTLD, SMA and AD [3]. The role of hnRNP-U 
in neurodegenerative diseases is not fully understood, yet it commonly presents in neurodegenerative diseases.
As more is learned, the roles of hnRNPs in other diseases will also be discovered. Understanding the roles of hnRNPs in diseases will be beneficial for developing 
potential therapeutic targets. For example, RNA-mediated toxicity is a hallmark of many affected neurons in neurodegenerative diseases like ALS/FTLD [4]. 
Hopefully future targeted antibody therapy towards these RNA foci, can attenuate this RNA toxicity. This targeted RNA-based therapy will be a critical step in 
reducing the expression level of the disease-propagating proteins. This suggests the addition of HNRNPU to all seizure-related diagnostic panels. We would also 
recommend including the HNRNPU-related disorders in a differential diagnosis of BRUE and recurrent apneic episodes as any underlying clonic activity may be 
profoundly subtle.
• HNRNPU is a is a highly conserved protein responsible for 
assisting spliceosomes in mediating transcription and 
alternative splicing activity.
• HNRNPU has been involved in neurodevelopmental and 
neurodegenerative diseases.  
• Recently, Durkin et al (PMID: 32319732) reported 21 
previously unreported probands with variable presentation, 
but usually with hypotonia, global developmental delays, and 
seizures [1].
• We describe a patient with a history of BRUE and mild unique 
facial features who was identified to have a pathogenic de 
novo nonsense mutation in HNRNPU (c.803+2T>C; p. ?). The 
variants are listed in Table 1.
Pertinent Physical Findings
Facial/Physical Characteristics: Telecanthus, broad nasal bridge, and short 
palpebral fissures. Additionally, a single transverse palmar crease (right hand).
CLINICAL COURSE:
• PREGNANCY HISTORY: A choroid plexus cyst was identified 
on a 20-week anatomy scan but resolved by 28 weeks. NIPT 
was negative. 
• DEVELOPMENTAL HISTORY: Gross motor skills were delayed 
about 6 months. He was able to sit by himself at 14 months, pull 
up to stand at 18 months, cruise at 20 months and walk at 20 
months. At 2 years old, he was babbling and speaking 5-10 
words. He communicated with hand gestures and could 
understand simple directions. He was responding to his name 
being called.
• FIRST ADMISSION (4 months old): Admitted following first 
apneic spell. 
• Imaging including CT, MRI, CXR, ENT, Holter monitor, 
and Echo. Apnea was determined to be due to 
gastroesophageal reflux (by exclusion).
• He started on reflux medications at 6 months of age, 
which helped prevent future episodes. He had no further 
episodes until he was taken off medication at 18 months 
old, resulting in restarting the reflux medication.
• At his 4-month inpatient stat, an episode was captured 
on video EEG, but without EEG correlate. Our patient 
was started on an AED and placed on 1.5 ml PO BID 
(150 mg) of Keppra (Levetiracetam), to go along with his 
normal bacitracin (topical – BID) and famotidine (dosing 
weight, oral – every 12 hrs).
• Additional apneic events occurred at 6, 18, 25,  and 26 months. 
• SECOND ADMISSION (28 months old): Admitted due to recur-
rent apneic spells and global developmental delay. Genetics 
was consulted. The latest episode at 26 and 28 months 
involved multiple apneic spells within a short period of time. 
INTRODUCTION:
Cardiovascular: Extensive history of tachycardia with apneic and 
acrocyanotic spells, with first onset at 4 months. Apneic events reoccurred at 6, 
18, 25, and 26 months of life. These apneic spells usually occurred within 30 
minutes of feeding. During these spells, our patient becomes completely limp and 
appears unconscious. Atrial septal defect, sinus rhythm with intermittent 1st degree 
AV block, blocked premature atrial contractions, left axis deviation, right bundle 
branch block, and a Left Ventricular Ejection Fraction of 67%, small secundum 
atrial septal defect (ASD) with small left-to-right shunting. 
Gastrointestinal: Feeding aversion history with history of significant reflux.
Neurological: Global developmental delay, hypotonia, dyspraxia with cognitive 
disability, T2/FLAIR hyperintense signal in the white matter of the parietal lobes, 
left greater than right (could be due to incomplete myelination in this region), 
generalized slowing indicative of a mild nonspecific encephalopathy, partial onset 
seizures with eye opening.
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Table 1: Chromosomal Sequencing Analysis (20,095 Gene Panel; gene sequencing with 
deletion and duplication analysis; genome-wide copy number analysis; TRIO).
